The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver College of Medicine and a member of the U.S. Food and Drug Administration’s ...

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced on Monday that their updated COVID-19 vaccine elicited a robust immune response in a late-stage trial among adults aged 65 and older, as well as ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...